In-vivo activated T-cell depletion to prevent GVHD.
Phase of Trial: Phase II/III
Latest Information Update: 19 Mar 2012
At a glance
- Drugs Basiliximab (Primary) ; Ciclosporin; Cyclophosphamide; Fludarabine; Mycophenolate mofetil
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 19 Mar 2012 Actual patient number changed from 11 to 10 as reported by ClinicalTrials.gov.
- 06 Jan 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.